Korea Exchange · Healthcare
Dong-A Socio Holdings stock from India: price, numbers and tax
Dong-A Socio Holdings (000640) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Dong-A Socio Holdings at a glance
- Price
- ₩93,000.00-₩1,700.00 (1.80%)
- Market cap
- ₩626.13B
- Day range
- ₩92,700.00 – ₩95,300.00
- P/E
- 7.43
- Dividend yield
- 1.83%
- Volume
- 8.28K
- 1 month
- +2.20%
- 6 months
- -0.64%
- YTD
- -15.15%
- 1 year
- -14.85%
- 5 years
- -10.31%
Dong-A Socio Holdings statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩1.4T | ₩1.3T | ₩1.1T | ₩1.0T | ₩881.9B |
| Gross profit | ₩439.5B | ₩408.1B | ₩374.9B | ₩294.4B | ₩281.5B |
| Operating income | ₩97.8B | ₩82.1B | ₩76.9B | ₩37.9B | ₩61.6B |
| Net income | ₩90.9B | ₩58.0B | ₩58.0B | ₩11.2B | ₩60.3B |
| Earnings per share | ₩13,718.00 | ₩9,011.65 | ₩9,006.80 | ₩1,732.04 | ₩9,483.50 |
| EBITDA | ₩193.1B | ₩194.9B | ₩141.4B | ₩88.1B | ₩137.0B |
| Total assets | ₩2.1T | ₩2.0T | ₩2.0T | ₩1.7T | ₩1.7T |
| Total debt | ₩662.6B | ₩740.0B | ₩691.9B | ₩552.1B | ₩537.6B |
| Cash and short-term investments | ₩145.8B | ₩127.3B | ₩160.5B | ₩105.8B | ₩158.5B |
| Shareholders' equity | ₩1.1T | ₩1.0T | ₩1.0T | ₩982.0B | ₩965.2B |
| Operating cash flow | ₩203.4B | ₩83.0B | ₩158.7B | ₩75.9B | ₩131.1B |
| Free cash flow | ₩154.1B | ₩7.4B | −₩825.3M | −₩2.7B | ₩52.4B |
| Capital expenditure | −₩49.3B | −₩75.6B | −₩159.5B | −₩78.6B | −₩78.7B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Daewoong pharmaceutical | 069620.KS | ₩108,500.00 | ₩1.25T |
| Ildong Pharmaceutical | 249420.KS | ₩14,020.00 | ₩441.74B |
| Kwang Dong Pharmaceutical | 009290.KS | ₩6,920.00 | ₩343.65B |
| Dong-A ST | 170900.KS | ₩34,950.00 | ₩337.05B |
| Korea United Pharm | 033270.KS | ₩17,860.00 | ₩257.93B |
| Chong Kun Dang | 001630.KS | ₩37,250.00 | ₩177.33B |
| Dongwha Pharm | 000020.KS | ₩5,360.00 | ₩148.57B |
| Jeil Pharmaceutical | 271980.KS | ₩10,050.00 | ₩147.78B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Dong-A Socio Holdings from India
What Dong-A Socio Holdings does
Dong-A Socio Holdings Co., Ltd., established in Seoul, South Korea in 1932, maintains a prominent role in the pharmaceutical industry both within South Korea and globally. Its diverse product range includes well-known items such as Bacchus, Benachio, and Tempo, alongside various infection management solutions and advanced imaging equipment like the FX-V1 and CLS-S7, which are utilized for surgical and diagnostic purposes. Dong-A Socio Holdings operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Dong-A Socio Holdings shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.